American Society of Retina Specialists

A perspective on what's moved virtually, and what hasn't, since the pandemic began in March.

In a phase 1b study presented virtually during ASRS 2020, investigators found a reduction in central subfield thickness after 12 weeks of OPT-302 combined with aflibercept injections.

An interview with a Cleveland Clinic investigator on adjusting macular edema screening methods.

The mean number of injections in the studies over 12 months was 9.36 ± 2.66, with a mean change in ETDRS letters was 7.86 ± 1.37.

Interim findings from a cross-sectional study shows a correlation between worse cognitive scoring and a greater rate of intravitreal injections.

A total of 115 of 200 examined eyes had some form of diabetic retinopathy in data presented at the ASRS 2020 virtual meeting.

Patients demonstrate visual gains from baseline but mean visual acuity worsens between 2 and 5 years.

In research presented at ASRS 2020, investigators found 56% of patients with PDR had a DME code, with a sensitivity of 85%.

A new analysis of a trio of intravitreal agents show maintained visual acuity in treatment-naive patients for at least 5 years.

The findings support treating eyes with the condition before they progress to proliferative diabetic retinopathy.

The specialty is on the precipice of advancement. What gets it over the hurdle?

In a study presented at ASRS 2020, investigators find an improvement in DRSS is not correlated with a change in best corrected visual acuity.

The implementation of teleretinal screening could improve clinic workflow.

Using the 4 JAMA benchmarks, investigators do not find any online articles that are entirely accurate and accountable.

The findings of the study highlight the importance of screening eye exams from index diagnosis.

Steroids are often prescribed for diabetic macular edema following ineffectiveness of laser photocoagulation and anti-VEGF.

The findings demonstrate the importance of providers to manage diabetes, diabetic retinopathy, and mental illness comorbidities.

A large proportion of nAMD patients treated with anti-VEGF therapies continue to have active disease and fluid.

Top websites for macular degeneration content do not necessarily have better quality information or readability.

In data presented virtually during the ASRS 2020 meeting, investigators find X-82 is non inferior in visual acuity outcomes.

The addition of oral zeaxanthin reduces the risk of subfoveal choroidal neovascularization development compared to previously published studies.

A look at how the specialty functions in telemedicine, and how it could work better with primary care physicians and endocrinologists.

How the condition affects both the vision and mindset of patients, and what clinical outcomes for anti-VEGF research do to address it.

New phase 1/2 data shows AAV-RGPR may benefit a previously untreated population of inherited retina disease boys and young men.

A look at how primary care patients begin to present with diabetic retinopathy risk.

New PANORAMA findings could give ophthalmologists confidence in longer time between administrations after year 2.

A former D.C. healthcare attorney and founder of the Macular Degeneration Association discusses legal problems faced by retina specialists when providing care to their patients with AMD.

Chirag Jhaveri, MD, took part in a Q&A about the results of the phase 3 HAWK and HARRIER studies examining brolucizumab for treatment of nAMD.

Results of a study from investigators at the Retina Center of Minnesota found that same-day injections were preferred by more than 97% of patients.

Manjot Gill, MD, discusses the results of her study which found early diagnosis and treatment of neovascular age-related macular degeneration could help save a patient’s vision.